Literature DB >> 18072493

Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test.

Gerhard Glatting1, Peter Kletting, Sven N Reske, Kathrin Hohl, Christina Ring.   

Abstract

In many circumstances of data fitting one has to choose the optimal fitting function or model among several alternatives. Criteria or tests on which this decision is based are necessary and have to be well selected. In this preliminary analysis the application of the corrected Akaike information criterion is demonstrated considering the example of determining pharmacokinetic parameters for the blood serum time activity curves of 111In-labeled anti-CD66 antibody. Another model selection criterion, the F-test, is used for comparison. For the investigated data the corrected Akaike information criterion has proved to be an effective and efficient approach, applicable to nested and non-nested models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072493     DOI: 10.1118/1.2794176

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  63 in total

1.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

2.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

3.  Behavioral sleep-wake homeostasis and EEG delta power are decoupled by chronic sleep restriction in the rat.

Authors:  Richard Stephenson; Aimee M Caron; Svetlana Famina
Journal:  Sleep       Date:  2015-05-01       Impact factor: 5.849

4.  The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam.

Authors:  Beitske E Smink; Berendina J A Hofman; Albert Dijkhuizen; Klaas J Lusthof; Johan J de Gier; Antoine C G Egberts; Donald R A Uges
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

5.  Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

Authors:  Anna E Kettermann; Luigi Ferrucci; Bruce J Trock; E Jeffrey Metter; Stacy Loeb; H Ballentine Carter
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

6.  Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images.

Authors:  F Botta; A Mairani; R F Hobbs; A Vergara Gil; M Pacilio; K Parodi; M Cremonesi; M A Coca Pérez; A Di Dia; M Ferrari; F Guerriero; G Battistoni; G Pedroli; G Paganelli; L A Torres Aroche; G Sgouros
Journal:  Phys Med Biol       Date:  2013-11-21       Impact factor: 3.609

7.  Pharmacokinetic analysis of tissue microcirculation using nested models: multimodel inference and parameter identifiability.

Authors:  Gunnar Brix; Stefan Zwick; Fabian Kiessling; Jürgen Griebel
Journal:  Med Phys       Date:  2009-07       Impact factor: 4.071

8.  Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue.

Authors:  Michel Koole; June van Aalst; Martijn Devrome; Nathalie Mertens; Kim Serdons; Brigitte Lacroix; Joel Mercier; David Sciberras; Paul Maguire; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-18       Impact factor: 9.236

9.  Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input.

Authors:  Sudheer D Rani; Samuel T Nemanich; Nicole Fettig; Kooresh I Shoghi
Journal:  Nucl Med Biol       Date:  2013-02-28       Impact factor: 2.408

10.  An evaluation of R2 as an inadequate measure for nonlinear models in pharmacological and biochemical research: a Monte Carlo approach.

Authors:  Andrej-Nikolai Spiess; Natalie Neumeyer
Journal:  BMC Pharmacol       Date:  2010-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.